Signify Bio
Biotechnology company developing in situ protein therapeutics by combining engineered signal peptide control with mRNA-encoded design and non-viral delivery systems. The company focuses on controlling secretion and intracellular localization of nucleic-acid-encoded proteins, delivery formulation engineering for tissue specificity and endosomal escape, computational design of signal peptides, and access to scalable nucleic acid and lipid nanoparticle manufacturing through an academic partnership.
Industries
Nr. of Employees
small (1-50)
Products
Platform for signal peptide-engineered nucleic acid design
Modular platform to engineer signal peptides that control secretion and intracellular localization of nucleic-acid-encoded proteins for in situ therapeutic protein production.
Ionizable phospholipid LNP delivery system
Lipid nanoparticle delivery formulations based on ionizable phospholipids engineered for enhanced endosomal escape and tissue specificity to deliver nucleic acid payloads.
Platform for signal peptide-engineered nucleic acid design
Modular platform to engineer signal peptides that control secretion and intracellular localization of nucleic-acid-encoded proteins for in situ therapeutic protein production.
Ionizable phospholipid LNP delivery system
Lipid nanoparticle delivery formulations based on ionizable phospholipids engineered for enhanced endosomal escape and tissue specificity to deliver nucleic acid payloads.
Expertise Areas
- Protein therapeutics development
- Signal peptide engineering
- Nucleic acid therapeutics (mRNA-encoded proteins)
- Lipid nanoparticle delivery
Key Technologies
- mRNA-encoded protein therapeutics
- Engineered signal peptides
- Ionizable phospholipid lipid nanoparticles
- Endosomal escape-enhanced delivery